Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical News Today (MNT)Trial Finds 2 Strategies to Maintain Weight Loss Results After Stopping GLP-1s

⚠️ Small Study / Early Comparative Evidence

A 39-person pilot trial evaluated weight maintenance after GLP-1 discontinuation among adults who had previously lost more than 10% of body weight. Over four months, participants receiving medically tailored meals or app-based behavioral support regained less weight than those receiving usual care. The study was designed primarily around intervention adherence and satisfaction and was not powered to establish definitive efficacy.


Clinical Considerations

  • Estimated weight regain reached 10.75% with usual care, compared with 3.58% with medically tailored meals and 3.60% with app-based support.
  • Monthly regain averaged 2.94% in the control group versus less than 1% in each intervention group.
  • Diet-quality scores were similar overall, although the app group showed a modest trend toward higher diet quality.
  • The four-month follow-up cannot establish durability or determine whether either strategy supports longer-term weight maintenance.
  • The 39-person sample, limited geographic and demographic diversity, self-reported measures, and limited blinding restrict generalizability.
  • Both interventions produced an early clinical signal, but the study was not powered for definitive comparative efficacy.

Practice Applications

  • Recognize weight maintenance after GLP-1 discontinuation as a distinct phase of obesity management that may require continued follow-up.
  • Discuss behavioral and nutrition support when patients anticipate or experience medication discontinuation, consistent with the individual’s broader obesity-management plan.
  • Interpret these interventions as preliminary strategies rather than established replacements for continued pharmacotherapy.
  • Avoid assuming equivalent effectiveness between app-based support and medically tailored meals from this small pilot.
  • Monitor post-discontinuation weight trajectory when GLP-1 therapy ends rather than assuming previous weight loss will remain stable.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form